BUFENCON INJECTION

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

BETAMETHASONE DIPROPIONATE EQV BETAMETHASONE; BETAMETHASONE PHOSPHATE DISODIUM EQV BETAMETHASONE

Available from:

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

ATC code:

H02AB01

Dosage:

5 mg/ml

Pharmaceutical form:

INJECTION

Composition:

BETAMETHASONE DIPROPIONATE EQV BETAMETHASONE 5 mg/ml; BETAMETHASONE PHOSPHATE DISODIUM EQV BETAMETHASONE 2 mg/ml

Administration route:

INTRAMUSCULAR, INTRADERMAL

Prescription type:

Prescription Only

Manufactured by:

YUNG SHIN PHARMACEUTICAL IND CO LTD

Authorization status:

ACTIVE

Authorization date:

1994-07-15

Summary of Product characteristics

causes which may include cataract, glaucoma or rare diseases such as
central serous chorioretinopathy
(CSCR) which have been reported after use of systemic and topical
corticosteroids.
DRUG INTERACTIONS:
1. Betamethasone may reduce the plasma levels of salicylates.
2. Phenobarbitone, by reducing liver enzymes, may increase the
clearance of betamethasone.
3. Phenytoin may alter the metabolism of corticosteroids.
4. The hyperglycaemic effect of betamethasone may offset the
hypoglycaemic effect of oral
antidiabetic drugs.
ADVERSE EFFECTS:
Fluid and electrolyte, musculoskeletal, gastrointestinal,
dermatologic, neurologic, endocrine,
vision blurred, ophthalmic and metabolic disturbances may occur.
PACKAGINGS:
Box of 1 mL x 50 Ampules.
Box of 5 mL x 10 Vials.
Manufacturer:
YUNG SHIN PHARMACEUTICAL IND. CO., LTD.
TACHIA, TAICHUNG, TAIWAN, R.O.C.
Imported by:
YUNG SHIN PHARMACEUTICAL (S) PTE. LTD.
10 Ubi Crescent, #06-57/58 Ubi Techpark,
Singapore 408564.
®
2147912
R
Bufencon Injection provides a unique combination of highly soluble and
slightly soluble esters of
betamethasone that produces marked, prompt, and sustained
anti-inflammatory, anti-rheumatic,
and anti-allergic effects.
INGREDIENTS:
EACH ML CONTAINS:
Betamethasone (as dipropionate)
............................................................................................
5 mg
Betamethasone (as phosphate disodium)
................................................................................
2 mg
ACTIONS:
1. Betamethasone decreases or prevents tissue responses to
inflammatory processes, thereby reducing
the development of symptoms of inflammation without affecting the
underlying cause. It inhibits
accumulation of inflammatory cells including macrophages and
leukocytes at sites of
inflammation.
2. Prompt therapeutic activity in corticosteroid-responsive conditions
is achieved by the soluble
ester, betamethasone sodium phosphate, which is quickly absorbed after
injection. Sustained
activity is provided by betamethasone dipropionate, which is only
slightly so